
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Beta Bionics, Inc. Common Stock (BBNX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: BBNX (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -0.73% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 945.12M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 8.89 - 24.50 | Updated Date 06/22/2025 |
52 Weeks Range 8.89 - 24.50 | Updated Date 06/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -104.64% | Operating Margin (TTM) -65.71% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 891525977 | Price to Sales(TTM) 17.82 |
Enterprise Value 891525977 | Price to Sales(TTM) 17.82 | ||
Enterprise Value to Revenue 16.81 | Enterprise Value to EBITDA - | Shares Outstanding 43334300 | Shares Floating 41336549 |
Shares Outstanding 43334300 | Shares Floating 41336549 | ||
Percent Insiders 6.74 | Percent Institutions 55.22 |
Upturn AI SWOT
Beta Bionics, Inc. Common Stock
Company Overview
History and Background
Beta Bionics is a private company focused on developing and commercializing innovative technologies for diabetes management. Founded to address unmet needs in automated insulin delivery, it evolved from research conducted at Boston University.
Core Business Areas
- Automated Insulin Delivery: Develops and commercializes automated insulin delivery (AID) systems, also known as artificial pancreas systems, for people with diabetes.
Leadership and Structure
Sean Saint is the CEO of Beta Bionics. The company's structure revolves around research and development, regulatory affairs, and commercialization of their iLet Bionic Pancreas system.
Top Products and Market Share
Key Offerings
- iLet Bionic Pancreas: The iLet Bionic Pancreas system is an AID system that automates insulin dosing decisions. Market share information is proprietary and not publicly disclosed as it is a private company. Competitors include Medtronic (MDT), Insulet (PODD), and Tandem Diabetes Care (TNDM).
Market Dynamics
Industry Overview
The diabetes management industry is experiencing growth driven by technological advancements in AID systems, continuous glucose monitoring (CGM), and connected devices. The industry is competitive with established players and emerging innovators.
Positioning
Beta Bionics is positioned as an innovator in AID technology with the iLet Bionic Pancreas, aiming to improve glycemic control and reduce the burden of diabetes management for users. Their competitive advantage lies in their bionic pancreas technology.
Total Addressable Market (TAM)
The global diabetes management market is projected to reach hundreds of billions of dollars. Beta Bionics is targeting a portion of this TAM focused on automated insulin delivery systems.
Upturn SWOT Analysis
Strengths
- Innovative bionic pancreas technology
- Focus on automated insulin delivery
- Strong scientific foundation
Weaknesses
- Limited financial resources as a private company
- Dependence on a single product
- Relatively smaller market presence compared to larger competitors
Opportunities
- Expanding market for AID systems
- Partnerships with healthcare providers and insurers
- Potential for international expansion
Threats
- Competition from established medical device companies
- Regulatory hurdles and reimbursement challenges
- Technological obsolescence
Competitors and Market Share
Key Competitors
- MDT
- PODD
- TNDM
Competitive Landscape
Beta Bionics faces strong competition from established players like Medtronic, Insulet, and Tandem Diabetes Care. Its competitive advantage lies in its innovative technology, but it needs to scale up to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not publicly available for Beta Bionics.
Future Projections: Future growth projections are dependent on successful commercialization and adoption of the iLet Bionic Pancreas system.
Recent Initiatives: Recent initiatives include securing regulatory approvals for their products and expanding their commercial infrastructure.
Summary
Beta Bionics is an innovative company with its bionic pancreas system which makes their product cutting edge. They have a competitive landscape against established players in the market, where scaling to meet demands and commercialization will be vital for growth. Securing partnerships, reimbursement, and regulatory approvals are all key factors. The lack of financial disclosure due to its private status makes it hard to get a precise idea how well they are doing as a company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is based on publicly available information and analyst estimates. Actual performance may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Beta Bionics, Inc. Common Stock
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2025-01-30 | President, CEO & Director Mr. Sean T. Saint PE | ||
Sector Healthcare | Industry Medical Devices | Full time employees 352 | Website https://www.betabionics.com |
Full time employees 352 | Website https://www.betabionics.com |
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.